Search research articles
Contact Us
Filters
Showing results (221-230 of 246) with videos related to
Page
of 25
Sort By:
The New England Journal of Medicine
|
January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
Richard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)
Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The New England Journal of Medicine
|
December 8, 2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C Byrd, Bonnie Harrington, Susan O'Brien, et al.
Leukemia
|
June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J R Brown, P Hillmen, S O'Brien, et al.
Leukemia
|
November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Blood
|
April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
Pinkal M Desai, Janice Brown, Saar Gill, et al.
Haematologica
|
February 22, 2020
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 246) with videos related to
Sort By:
Page
of 25
The New England Journal of Medicine
|
January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
Richard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)
Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The New England Journal of Medicine
|
December 8, 2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C Byrd, Bonnie Harrington, Susan O'Brien, et al.
Leukemia
|
June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J R Brown, P Hillmen, S O'Brien, et al.
Leukemia
|
November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Blood
|
April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2021
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
Pinkal M Desai, Janice Brown, Saar Gill, et al.
Haematologica
|
February 22, 2020
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Nicole Lamanna, Lindsey E Roeker, et al.
Page
of 25